Special Issue "SARS-CoV-2 Serological Studies around the World"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".

Deadline for manuscript submissions: closed (20 October 2023) | Viewed by 1351

Special Issue Editors

UMR Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Université de La Réunion, St Denis, La Réunion, France
Interests: RNA viruses; infectious viruses; coronaviruses; wild fauna; reverse genetic; epidemiology
1. Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhon Pathom 73170, Thailand
2. Unité des Virus Émergents, Aix Marseille University, IRD 190, INSERM U1207, IHU Méditerranée Infection, 13005 Marseille, France
Interests: SARS-CoV-2; epidemiology; infectious diseases; molecular and serological diagnostics
Swine and Poultry Infectious Diseases Research Center (CRIPA), Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC J2S 2M2, Canada
Interests: virology; veterinary microbiology; innate immune response; animal model; pig; vaccines; mucosal immunology; respiratory and intestinal infectious diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for COVID-19, a severe pneumonia leading to respiratory distress, has now spread around the world with more than 615 million people being infected.

During the course of the pandemic, several variants carrying amino acid changes in the entire genome of SARS-CoV-2 emerged worldwide. The emergence of these variants was often accompanied by a loss of effectiveness of immune efficiency, induced by primary infection, vaccination or therapeutic treatments.

The need for serological investigation to analyze the antibody responses, titer and duration elicited by primary infection or vaccination against the circulating variants will greatly help the identification of the populations at risk of re-infection and will help monitor the efficacy of COVID-19 vaccines, thus, accelerating the public health policy decision.

For this Special Issue, both reviews and research articles describing the SARS-CoV-2 sero-epidemiology using robust system or gold standard tools will be welcome.  

Dr. Julien Mélade
Dr. Paola Mariela Saba Villarroel
Prof. Dr. François Meurens
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • SARS-CoV-2
  • variant
  • serology
  • immunization
  • epidemiology

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


10 pages, 613 KiB  
Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study
Vaccines 2023, 11(3), 493; https://doi.org/10.3390/vaccines11030493 - 21 Feb 2023
Cited by 1 | Viewed by 1055
Hematological malignancies (HMs) have heterogeneous serological responses after vaccination due to disease or treatment. The aim of this real-world study was to analyze it after Pfizer-BioNT162b2 mRNA vaccination in 216 patients followed up for 1 year. The first 43 patients had an initial [...] Read more.
Hematological malignancies (HMs) have heterogeneous serological responses after vaccination due to disease or treatment. The aim of this real-world study was to analyze it after Pfizer-BioNT162b2 mRNA vaccination in 216 patients followed up for 1 year. The first 43 patients had an initial follow-up by a telemedicine (TM) system with no major events reported. The anti-spike IgG antibodies were checked 3–4 weeks post-first vaccination and every 3–4 months, by two standard bioassays and a rapid serological test (RST). Vaccine boosts were given when the level was <7 BAU/mL. Patients who did not seroconvert after 3–4 doses received tixagevimab/cilgavimab (TC). Fifteen results were discordant between two standard bioassays. Good agreement was observed between the standard and RST in 97 samples. After two doses, 68% were seroconverted (median = 59 BAU/mL) with a median of 162 BAU/mL and 9 BAU/mL, respectively, in untreated and treated patients (p < 0.001), particularly for patients receiving rituximab. Patients with gammaglobulin levels < 5 g/L had reduced seroconversion compared to higher levels (p = 0.019). The median levels were 228 BAU/mL post-second dose if seroconverted post-first and second, or if seroconverted only post-second dose. A total of 68% of post-second dose negative patients were post-third dose positive. A total of 16% received TC, six with non-severe symptomatic COVID-19 within 15–40 days. Personalized serological follow-up should apply particularly to patients with HMs. Full article
(This article belongs to the Special Issue SARS-CoV-2 Serological Studies around the World)
Show Figures

Figure 1

Back to TopTop